Drugs / COVID Convalescent Plasma
COVID Convalescent Plasma
also known as
CCP · CCP, COVID-19 Convalescent Plasma · Convalescent plasma · COVID-19 Convalescent Plasma
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04412486 | Jun 2020 → Mar 2023 | COVID-19 | Gailen D. Marshall Jr., MD PhD | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT05904067 | Jun 2023 → Jan 2024 | COVID-19, disease related to hematopoietic stem cell transplant | Institute of Hematology & Blood Diseases Hospital, China | Unknown | Missed primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT04542941 Comparator | Jun → Dec 2020 | COVID-19 | Makerere University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID Convalescent Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04542941 ↗ |
| Known as | CCP | “Convalescent plasma (CCP) has been studied as a potential therapy for COVID-19” PMID 34376401 ↗ Aug 2021 |
| Known as | CCP, COVID-19 Convalescent Plasma | “CCP, COVID-19 Convalescent Plasma” NCT04412486 ↗ |
| Known as | Convalescent plasma | “Convalescent plasma (CCP) has been studied as a potential therapy for COVID-19” PMID 34376401 ↗ Aug 2021 |
| Known as | COVID-19 Convalescent Plasma | “General objective The overall objective of this project is to assess the safety and efficacy of COVID-19 Convalescent Plasma in the treatment of COVID-19 in Uganda” NCT04542941 ↗ |
| Modality | Protein / enzyme biologic | “high titers of IgG antibody to this virus” NCT04412486 ↗ |
| Route | Other | “Transfusion of COVID-19 convalescent plasma to participants” NCT05904067 ↗ |